Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Consensus Rating of “Buy” from Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given an average recommendation of “Buy” by the seven analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is C$4.57.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$2.56 on Thursday. Medexus Pharmaceuticals has a 52-week low of C$1.71 and a 52-week high of C$5.56. The stock has a market capitalization of C$82.58 million, a PE ratio of 128.00 and a beta of 2.55. The stock’s 50 day moving average price is C$2.89 and its 200-day moving average price is C$2.79.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.